Showing results (231-240 of 261) with videos related to
Sort By:
Pageof 27
The Journal of Allergy and Clinical Immunology|February 11, 2018
New mechanism underlying IL-31-induced atopic dermatitisJianghui Meng, Masaki Moriyama, Micha Feld, et al.Cell Death & Disease|February 6, 2023
Regulation of immunological tolerance by the p53-inhibitor iASPPElliot H Akama-Garren, Paul Miller, Thomas M Carroll, et al.Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|December 28, 2004
Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind studyClifford J Rosen, Marc C Hochberg, Sydney L Bonnick, et al.Plos One|April 16, 2014
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosisRobert S Wallis, Rodney Dawson, Sven O Friedrich, et al.International Journal of Environmental Research and Public Health|February 20, 2020
A Cost and Cost-Benefit Analysis of the Stand More AT Work (SMArT Work) InterventionFehmidah Munir, Paul Miller, Stuart J H Biddle, et al.Annals of the Rheumatic Diseases|March 4, 2015
Paracetamol: not as safe as we thought? A systematic literature review of observational studiesEmmert Roberts, Vanessa Delgado Nunes, Sara Buckner, et al.Multimedia Manual of Cardiothoracic Surgery : MMCTS|January 14, 2014
Surgical management of hypoplastic left heart syndrome at the Birmingham Children's HospitalAlexander M Fabricius, Timothy J Jones, John Stickley, et al.Nucleic Acids Research|October 27, 2009
Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagentsC A Stein, J Bo Hansen, Johnathan Lai, et al.Endocrine-Related Cancer|February 16, 2022
Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumorsOlga Lakiza, Julian Lutze, Alyx Vogle, et al.Journal of Pharmacy Practice|August 30, 2017
Development of Glatopa® (Glatiramer Acetate): The First FDA-Approved Generic Disease-Modifying Therapy for Relapsing Forms of Multiple SclerosisChristine Bell, James Anderson, Tanmoy Ganguly, et al.Pageof 27